

**AMENDMENTS TO THE CLAIMS**

This listing of claims replaces all prior listings of claims in the application:

1-19 (Canceled)

20. (Previously presented) A method for treating a patient suffering from depression who has a sleep disturbance when treated with a selective serotonin reuptake inhibitor other than escitalopram without inducing a sleep disturbance comprising administering a daily pharmaceutically effective amount of escitalopram or a pharmaceutically acceptable salt thereof to the patient, wherein the daily dose is 2.5 to 10 mg of escitalopram or a pharmaceutically acceptable salt thereof.
21. (Canceled)
22. (Currently Amended) The method of claim 20, wherein the daily dose is 2.5 to 7.5 mg or less of escitalopram or a pharmaceutically acceptable salt thereof.
23. (Previously Presented) The method of claim 22, wherein the daily dose is 7.5 mg.
24. (Previously Presented) The method of claim 22, wherein the daily dose is 5 mg.
25. (Previously Presented) The method of claim 20, wherein the pharmaceutically acceptable salt is an oxalate salt.
26. (Canceled)
27. (Previously Presented) The method of claim 22, wherein the pharmaceutically acceptable salt is an oxalate salt.

28. (Previously Presented) The method of claim 23, wherein the pharmaceutically acceptable salt is an oxalate salt.
29. (Previously Presented) The method of claim 24, wherein the pharmaceutically acceptable salt is an oxalate salt.
30. (Previously Presented) The method of claim 25, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
31. (Canceled)
32. (Previously Presented) The method of claim 27, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
33. (Previously Presented) The method of claim 28, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
34. (Previously Presented) The method of claim 29, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.